drugset / Trial / NCT00503347
Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This trial is designed to assess the safety, tolerability, pharmacokinetics and viral kinetics after multiple infusions of bavituximab in patients co-infected with HCV and HIV.
Timeline
- Start
- 2007-07
- Primary completion
- 2011-03
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bavituximab | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | Bavituximab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Bavituximab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Bavituximab | Monoclonal antibody | 6 mg/kg | Intravenous |